Wave Life Sciences Ltd. (WVE) is a clinical-stage genetic medicines company headquartered in Singapore, with offices in Massachusetts, USA. The company is focused on developing nucleic acid therapies for the treatment of genetic diseases.
Wave's lead product candidate is suvodirsen, an investigational therapy for the treatment of Duchenne muscular dystrophy (DMD), a rare and fatal genetic disease that affects muscle function. Suvodirsen is designed to target a specific mutation in the DMD gene and promote the production of a functional dystrophin protein. Wave is also developing other product candidates for the treatment of various genetic diseases, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia.
As of September 30, 2021, Wave had cash, cash equivalents, and marketable securities of $242.5 million. The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.
In November 2021, Wave announced positive interim data from its Phase 1b/2a clinical trial of suvodirsen in patients with DMD. The data showed that suvodirsen was generally well-tolerated and demonstrated a statistically significant increase in dystrophin protein expression compared to placebo. The company plans to continue the development of suvodirsen and expects to initiate a Phase 3 clinical trial in the second half of 2022.
Wave's stock is listed on the NASDAQ stock exchange and has a market capitalization of approximately $1.3 billion as of February 21, 2023. The stock has experienced significant volatility in recent years and investors should carefully consider the risks associated with investing in a clinical-stage genetic medicines company.
|
